| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |